Roger S McIntyre1, Daisy Ng-Mak2, Chien-Chia Chuang3, Rachel Halpern4, Pankaj A Patel5, Krithika Rajagopalan6, Antony Loebel7. 1. University of Toronto, MDPU-BCDF, Toronto, Canada. 2. Sunovion Pharmaceuticals Inc., Marlborough, MA, USA. Electronic address: Daisy.Ng-Mak@Sunovion.Com. 3. Vertex Pharmaceuticals Inc., Boston, MA, USA. 4. Optum, Prairie, MN, USA. 5. Kantar Health, New York, NY, USA. 6. Sunovion Pharmaceuticals Inc., Marlborough, MA, USA. 7. Sunovion Pharmaceuticals Inc., Fort Lee, NY, USA.
Abstract
BACKGROUND: To compare outcomes for individuals with major depressive disorder (MDD) with or without subthreshold hypomania (mixed features) in naturalistic settings. METHODS: Using the Optum Research Database (1/1/2009─10/31/2014), a retrospective analysis of individuals newly diagnosed with MDD was conducted. Continuous enrollment for 12-months before and after the initial MDD diagnosis was required. MDD with subthreshold hypomania (mixed features) (MDD-MF) was defined based on ≥1 hypomania diagnosis within 30 days after an MDD diagnosis during the one-year follow-up period, in the absence of bipolar I diagnoses. Psychiatric medication use, healthcare utilization, and costs during the one-year follow-up period were compared using multivariate logistic and gamma regressions, controlling for baseline differences. RESULTS: Of 130,626 MDD individuals, 652 (0.5%) met the operational definition of MDD-MF. Compared to the MDD-only group, the MDD-MF group had more suicidality (2.0% vs. 0.5%), anxiety disorders (46.8% vs. 34.0%), and substance use disorders (15.5% vs. 6.1%, all P<0.001). More individuals with MDD-MF were treated with antidepressants (83.6% vs. 71.6%), mood stabilizers (50.5% vs. 2.7%), atypical antipsychotics (39.0% vs. 5.5%), and polypharmacy with multiple drug classes (72.1% vs. 22.7%, all P<0.001). Individuals with MDD-MF had higher hospitalizations rates (24.2% vs. 10.5%) and total healthcare costs (mean: $15,660 vs. $10,744, all P<0.001). LIMITATIONS: The commercial claims data used were not collected for research purposes and may over- or under-represent certain populations. No specific claims-based diagnostic code for MDD with mixed features exists. CONCLUSIONS: Greater use of mood stabilizers, atypical antipsychotics, polypharmacy, and healthcare resources provides evidence of the complexity and severity of MDD-MF. Identifying optimal treatment regimens for this population represents a major unmet medical need.
BACKGROUND: To compare outcomes for individuals with major depressive disorder (MDD) with or without subthreshold hypomania (mixed features) in naturalistic settings. METHODS: Using the Optum Research Database (1/1/2009─10/31/2014), a retrospective analysis of individuals newly diagnosed with MDD was conducted. Continuous enrollment for 12-months before and after the initial MDD diagnosis was required. MDD with subthreshold hypomania (mixed features) (MDD-MF) was defined based on ≥1 hypomania diagnosis within 30 days after an MDD diagnosis during the one-year follow-up period, in the absence of bipolar I diagnoses. Psychiatric medication use, healthcare utilization, and costs during the one-year follow-up period were compared using multivariate logistic and gamma regressions, controlling for baseline differences. RESULTS: Of 130,626 MDD individuals, 652 (0.5%) met the operational definition of MDD-MF. Compared to the MDD-only group, the MDD-MF group had more suicidality (2.0% vs. 0.5%), anxiety disorders (46.8% vs. 34.0%), and substance use disorders (15.5% vs. 6.1%, all P<0.001). More individuals with MDD-MF were treated with antidepressants (83.6% vs. 71.6%), mood stabilizers (50.5% vs. 2.7%), atypical antipsychotics (39.0% vs. 5.5%), and polypharmacy with multiple drug classes (72.1% vs. 22.7%, all P<0.001). Individuals with MDD-MF had higher hospitalizations rates (24.2% vs. 10.5%) and total healthcare costs (mean: $15,660 vs. $10,744, all P<0.001). LIMITATIONS: The commercial claims data used were not collected for research purposes and may over- or under-represent certain populations. No specific claims-based diagnostic code for MDD with mixed features exists. CONCLUSIONS: Greater use of mood stabilizers, atypical antipsychotics, polypharmacy, and healthcare resources provides evidence of the complexity and severity of MDD-MF. Identifying optimal treatment regimens for this population represents a major unmet medical need.
Keywords:
Drug utilization; Health services research; Healthcare administrative claims; Major depressive disorder; Major depressive disorder with mixed features; Mood disorders
Authors: Manish K Jha; Ashley L Malchow; Bruce D Grannemann; A John Rush; Madhukar H Trivedi Journal: Neuropsychopharmacology Date: 2018-08-15 Impact factor: 7.853
Authors: Roger S McIntyre; Martin Alda; Ross J Baldessarini; Michael Bauer; Michael Berk; Christoph U Correll; Andrea Fagiolini; Kostas Fountoulakis; Mark A Frye; Heinz Grunze; Lars V Kessing; David J Miklowitz; Gordon Parker; Robert M Post; Alan C Swann; Trisha Suppes; Eduard Vieta; Allan Young; Mario Maj Journal: World Psychiatry Date: 2022-10 Impact factor: 79.683
Authors: Ludovico Mineo; Alessandro Rodolico; Giorgio Alfredo Spedicato; Andrea Aguglia; Simone Bolognesi; Carmen Concerto; Alessandro Cuomo; Arianna Goracci; Giuseppe Maina; Andrea Fagiolini; Mario Amore; Eugenio Aguglia Journal: Eur Psychiatry Date: 2022-05-31 Impact factor: 7.156
Authors: Elena C Peterson; Hannah R Snyder; Chiara Neilson; Benjamin M Rosenberg; Christina M Hough; Christina F Sandman; Leoneh Ohanian; Samantha Garcia; Juliana Kotz; Jamie Finegan; Caitlin A Ryan; Abena Gyimah; Sophia Sileo; David J Miklowitz; Naomi P Friedman; Roselinde H Kaiser Journal: Front Hum Neurosci Date: 2022-04-14 Impact factor: 3.169
Authors: Mary K Lam; Lawrence T Lam; Kerryn Butler-Henderson; Jonathan King; Tahnee Clark; Peta Slocombe; Katherine Dimarco; Wendell Cockshaw Journal: Front Psychiatry Date: 2022-09-09 Impact factor: 5.435